AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Jun 25, 2024
32254_dirs_2024-06-25_a1bda155-2490-4ce3-bc45-1cd278bcab61.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-06-23
Reporting Person: ADAMIS ANTHONY P (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-23 | Common Stock | M | 2000.00 | $0.00 | Acquired | 4000.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-23 | Restricted Stock Units | $0.00 | M | 2000.00 | Disposed | Common Stock (2000.00) | Direct |
Footnotes
F1: The restricted stock units vests in three ratable annual installments beginning June 23, 2023.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7